Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats

Molecular and Cellular Biochemistry

Volumn 249, Issue 1-2, 2003, Pages 53-57

  Umrani, Dhananjay N ^a   Bodiwala, Dipali N ^a   Goyal, Ramesh K ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

5 HT receptor; Diabetes; Platelet aggregation; Sarpogrelate

Indexed keywords

GLUCOSE; INSULIN; SARPOGRELATE; SEROTONIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; BULIMIA; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; DIET RESTRICTION; DOSE RESPONSE; DOWN REGULATION; GLUCOSE BLOOD LEVEL; HEART; HYPERGLYCEMIA; HYPERPHAGIA; HYPERTENSION; HYPOINSULINEMIA; INOTROPISM; INSULIN BLOOD LEVEL; NONHUMAN; POLYDIPSIA; RAT; STREPTOZOCIN DIABETES; TAIL; THROMBOCYTE; THROMBOCYTE AGGREGATION; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; MYOCARDIUM; PLATELET AGGREGATION; RATS; RECEPTORS, SEROTONIN; SEROTONIN; STREPTOZOCIN; SUCCINATES;

ANIMALIA;

EID: 0041974971     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024762002836     Document Type: Article

References (25)

1. 2 receptors in the central regulation of the cardiovascular system. Pharm Rev 46: 231-243, 1994
2. Sharma SK, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla NS: Inhibition of serotonin induced vascular muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther 290: 1475-1481, 1999
3. 2 receptors in cultured fetal mouse ventricular myocytes. Circ Res 66: 1474-1483, 1990
4. Laer S, Remmers F, Scholz H, Stein B, Muller FU, Neumann J: Receptors mechanisms involved in the 5-HT induced inotropic action in the rat isolated atrium. Br J Pharmacol 123: 1182-1188, 1998
5. Page MM, Watkins PJ: The heart in diabetes: Autonomic neuropathy and cardiomyopathy. Clin Endocrinol Metab 6: 377-388, 1977
6. Dhalla NS, Pierce GN, Innes IR, Beamish RE: Pathogenesis of cardiac dysfunction in diabetes mellitus. Can J Cardiol 1: 263-281, 1985
7. Latifpour, McNeill JH: Cardiac autonomic receptors: Effects of long term experimental diabetes. J Pharmacol Exp Ther 230: 242-249, 1984
8. Hagen AA, Shirasawa Y, White RP: Experimental diabetes: Reduction of serotonin-induced vasoconstriction by meclofenamic acid in vitro Pharmacology 30: 197-204, 1985
9. James GM, Hodgson WC, Davis EA, Haynes JM: Attenuated 5-hydroxytryptamine receptor mediated responses in aortae from STZ-induced diabetic rats. Br J Pharmacol 111: 370-375, 1994
10. 2 receptor antagonist with platelet anti aggregatory properties. Drugs Today 30: 43-48, 1994
11. Pietraszek MH, Takada Y, Taminato A, Yoshimi T, Watanabe I, Takada A: The effect of MCI-9042 on serotonin induced platelet aggregation in type 2 diabetes mellitus. Thromb Res 70: 131-138, 1993
12. Kwaan HC, Colwell JA, Cruz S: Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 20: 236, 1972
13. Nakanishi M, Imamura H, Ikegami K, Goto K: Pharmacological investigations of Arzneimittelforschung 20: 1004-1009, 1970
14. Gagliardino JJ, Zieher LM, Iturriza FC, Hernandez RE, Rodriguez RR: Insulin release and glucose changes induced by serotonin. Horm Metab Res 3: 145-150, 1971
15. Lechin F, Coll-Garcia E, Van Der Dijs B, Pena F, Bentolila A, Rivas C: The effect of serotonin (5-HT) on insulin secretion. Acta Physiol Lat Am 25: 339-346, 1975
16. Jacoby JH, Bryce GF: The acute pharmacological effects of serotonin on the release of insulin and glucagon in the intact rat. Arch Int Pharmacodyn Ther 235: 254-270, 1978
17. Botros M, Saba JA: The glycemic effects of serotonin (5-hydroxytryptamine). J Egypt Med Assoc 51: 41-47, 1968
18. 3) receptor agonists on blood glucose levels in rats. Biol Pharm Bull 19: 1384-1386, 1996
19. 2A receptor in peripherally administered serotonin-induced hyperglycemia in rats. Life Sci 57: 819-825, 1995
20. Ikeda K, Tojo K, Tokudome G, Hosoya T, Harada M, Nakao K: The effects of sarpogrelate on cardiomyocyte hypertrophy. Life Sci 67: 2991-2996, 2000
21. Hara H, Osakabe A, Kitajima Y, Kikumoto R: MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 65: 415-420, 1991
22. 2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res 84: 445-452, 1996
23. Furukawa K, Tanabe T, Hoshino S, Mishima Y, Shionoya S, Yoshizaki S: Therapeutic effects of sarpogrelate hydrochloride (MCI-9042) on chronic arterial occlusive diseases - a double-blind comparison with ticlopindine hydrochloride. J Clin Ther Med 7: 1747-1770, 1991
24. Nakamura K, Kariyazono H, Masuda H, Sakata R, Yamada: Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. Blood Coagul Fibrinolysis 12: 391-397, 2001
25. Saxena PR: Cardiovascular effects from stimulation of 5-hydroxytryptamine receptors. Fund Clin Pharmacol 3: 245-265, 1989